Biotech by one-year price change
How far the share price has moved over the last 52 weeks.
Moderna leads the 24 biotech ranked by one-year price change, at +755%, ahead of Kodiak Sciences (+396%) and Twist Bioscience (+340%). Figures as of 18 Nov 2026, 15:00 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 24
- First
- Moderna+755%
- Median
- +40.0%
- Combined market value
- NOK 8.2T
- Countries
- 5
Market values as of .
All countries▾
All sectors▾
Biotech▾
| # | Company | 1 year ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | ModernaMRNA · Health Care | +755% | NOK 800.3B | NOK 1,977.96 | 1.31% down | 755% up | ||
| 2 | Kodiak SciencesKOD · Health Care | +396% | NOK 62.2B | NOK 950.99 | 1.37% up | 396% up | ||
| 3 | Twist BioscienceTWST · Health Care | +340% | NOK 76.9B | NOK 1,127.32 | 3.86% up | 340% up | ||
| 4 | ImmunityBioIBRX · Health Care | +193% | NOK 66.3B | NOK 62.31 | 2.72% up | 193% up | ||
| 5 | Revolution MedicinesRVMD · Health Care | +131% | NOK 338B | NOK 1,562.70 | 0.89% down | 131% up | ||
| 6 | Adaptive BiotechnologiesADPT · Health Care | +88.1% | NOK 45.1B | NOK 278.91 | 1.02% up | 88% up | ||
| 7 | Kymera TherapeuticsKYMR · Health Care | +87.5% | NOK 102.4B | NOK 1,199.13 | 1.82% up | 87% up | ||
| 8 | CG OncologyCGON · Health Care | +85.3% | NOK 67.5B | NOK 755.96 | 1.18% down | 85% up | ||
| 9 | ExelixisEXEL · Health Care | +62.6% | NOK 162.6B | NOK 666.17 | 0.35% up | 63% up | ||
| 10 | BiogenBIIB · Health Care | +49.3% | NOK 358.9B | NOK 2,427.73 | 0.11% down | 49% up | ||
| 11 | Krystal BiotechKRYS · Health Care | +46.3% | NOK 88.3B | NOK 2,978.38 | 2.94% up | 46% up | ||
| 12 | ImmunovantIMVT · Health Care | +43.4% | NOK 67.3B | NOK 325.38 | 1.10% up | 43% up | ||
| 13 | Halozyme TherapeuticsHALO · Health Care | +36.6% | NOK 106.8B | NOK 936.65 | 0.71% up | 37% up | ||
| 14 | AmgenAMGN · Health Care | +33.7% | NOK 2.37T | NOK 4,381.03 | 1.28% down | 34% up | ||
| 15 | Gilead SciencesGILD · Health Care | +32.9% | NOK 2.04T | NOK 1,641.00 | 0.55% down | 33% up | ||
| 16 | Bio-TechneTECH · Health Care | +25.6% | NOK 110.7B | NOK 704.69 | 0.12% up | 26% up | ||
| 17 | VaxcytePCVX · Health Care | +22.2% | NOK 91B | NOK 574.59 | 0.19% down | 22% up | ||
| 18 | Neurocrine BiosciencesNBIX · Health Care | +20.2% | NOK 161.8B | NOK 1,598.26 | 0.60% down | 20% up | ||
| 19 | Scholar Rock HoldingSRRK · Health Care | +13.6% | NOK 56B | NOK 459.02 | 5.07% up | 14% up | ||
| 20 | QiagenQGEN · Health Care | +12.0% | NOK 99.4B | NOK 481.36 | 0.16% down | 12% up | ||
| 21 | RepligenRGEN · Health Care | +4.58% | NOK 106B | NOK 1,658.93 | 5.55% up | 5% up | ||
| 22 | argenxARGX · Health Care | +3.60% | NOK 586.2B | NOK 9,321.34 | 1.51% up | 4% up | ||
| 23 | BioNTechBNTX · Health Care | -16.3% | NOK 204.3B | NOK 823.89 | 0.18% up | 16% down | ||
| 24 | CRISPR TherapeuticsCRSP · Health Care | -20.9% | NOK 39.4B | NOK 405.77 | 4.28% up | 21% down |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Sums are converted from US dollars at today's exchange rate (1 USD = 9.6912 NOK).
Questions and answers
Which biotech rank first by one-year price change?
Moderna (+755%), Kodiak Sciences (+396%) and Twist Bioscience (+340%) are the top three of the 24 biotech ranked by one-year price change as of 18 Nov 2026, 15:00 UTC.
How many biotech are in this ranking?
24 are ranked by one-year price change.
What are these biotech worth together?
The 24 biotech ranked by one-year price change have a combined market value of NOK 8.2T as of 18 Nov 2026, 15:00 UTC.
What does ranking by one-year price change measure?
How far the share price has moved over the last 52 weeks.
Learn how this ranking works
All markets guides →- 52-week high and low: what the range tells you
A stock's 52-week high and low are the highest and lowest prices it reached over the past year. Where today's price sits in that range, from 0% at the low to 100% at the high, shows how the past year has gone. Sources differ on whether they use closing or intraday prices, so the same stock's range can differ slightly.
- Drawdown and recovery: why a 50% fall needs a 100% gain
A drawdown is how far a price has fallen from its previous peak, as a percentage of that peak. Recovery needs a larger gain than the fall, because the gain starts from a smaller base: a 20% drop needs a 25% rise to get back, a 50% drop needs 100%, and a 75% drop needs 300%.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Biotech by one-year price change”, data as of 18 November 2026. https://funkfolio.com/companies/category/biotech?by=year-change
Underlying data: Yahoo Finance; SEC EDGAR.